Lantern Pharma (LTRN) announced that the first patient has been dosed – as part of the expansion cohort – in Japan for its Phase 2 Harmonic clinical trial evaluating LP-300 in never-smoker patients with non-small cell lung cancer, or NSCLC, who have progressed after receiving treatment with tyrosine kinase inhibitors, or TKIs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LTRN:
Questions or Comments about the article? Write to editor@tipranks.com